Hypertrophic Obstructive Cardiomyopathy: Surgical Myectomy and Septal Ablation

Rick A. Nishimura, Hubert Seggewiss, Hartzell V Schaff

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Hypertrophic cardiomyopathy is a genetic disorder characterized by marked hypertrophy of the myocardium. It is frequently accompanied by dynamic left ventricular outflow tract obstruction and symptoms of dyspnea, angina, and syncope. The initial therapy for symptomatic patients with obstruction is medical therapy with β-blockers and calcium antagonists. However, there remain a subset of patients who have continued severe symptoms, which are unresponsive to medical therapy. These patients can be treated with septal reduction therapy, either surgical septal myectomy or alcohol septal ablation. When performed by experienced operators working in high-volume centers, septal myectomy is highly effective with a >90% relief of obstruction and improvement in symptoms. The perioperative mortality rate for isolated septal myectomy in most centers is <1%. Alcohol septal ablation is a less invasive treatment. In many patients, the hemodynamic and clinical results are comparable to that of septal myectomy. However, the results of alcohol septal ablation are dependent on the septal perforator artery supplying the area of the contact between the hypertrophied septum and the anterior leaflet of the mitral valve. There are some patients, particularly younger patients with severe hypertrophy, who do not uniformly experience complete relief of obstruction and symptoms. Both techniques of septal reduction therapy are highly operator dependent. The final decision as to which approach should be selected in any given patient is dependent up patient preference and the availability and experience of the operator and institution at which the patient is being treated.

Original languageEnglish (US)
Pages (from-to)771-783
Number of pages13
JournalCirculation Research
Volume121
Issue number7
DOIs
StatePublished - Sep 15 2017
Externally publishedYes

Fingerprint

Hypertrophic Cardiomyopathy
Alcohols
Hypertrophy
Therapeutics
Ventricular Outflow Obstruction
Inborn Genetic Diseases
Patient Preference
Syncope
Mitral Valve
Dyspnea
Myocardium
Arteries
Hemodynamics
Calcium
Mortality

Keywords

  • athletes
  • blood pressure
  • cardiomyopathy, hypertrophic
  • dyspnea
  • hypertrophy

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Hypertrophic Obstructive Cardiomyopathy : Surgical Myectomy and Septal Ablation. / Nishimura, Rick A.; Seggewiss, Hubert; Schaff, Hartzell V.

In: Circulation Research, Vol. 121, No. 7, 15.09.2017, p. 771-783.

Research output: Contribution to journalReview article

Nishimura, Rick A. ; Seggewiss, Hubert ; Schaff, Hartzell V. / Hypertrophic Obstructive Cardiomyopathy : Surgical Myectomy and Septal Ablation. In: Circulation Research. 2017 ; Vol. 121, No. 7. pp. 771-783.
@article{920b73a217ef4744b6944d09f69e2f13,
title = "Hypertrophic Obstructive Cardiomyopathy: Surgical Myectomy and Septal Ablation",
abstract = "Hypertrophic cardiomyopathy is a genetic disorder characterized by marked hypertrophy of the myocardium. It is frequently accompanied by dynamic left ventricular outflow tract obstruction and symptoms of dyspnea, angina, and syncope. The initial therapy for symptomatic patients with obstruction is medical therapy with β-blockers and calcium antagonists. However, there remain a subset of patients who have continued severe symptoms, which are unresponsive to medical therapy. These patients can be treated with septal reduction therapy, either surgical septal myectomy or alcohol septal ablation. When performed by experienced operators working in high-volume centers, septal myectomy is highly effective with a >90{\%} relief of obstruction and improvement in symptoms. The perioperative mortality rate for isolated septal myectomy in most centers is <1{\%}. Alcohol septal ablation is a less invasive treatment. In many patients, the hemodynamic and clinical results are comparable to that of septal myectomy. However, the results of alcohol septal ablation are dependent on the septal perforator artery supplying the area of the contact between the hypertrophied septum and the anterior leaflet of the mitral valve. There are some patients, particularly younger patients with severe hypertrophy, who do not uniformly experience complete relief of obstruction and symptoms. Both techniques of septal reduction therapy are highly operator dependent. The final decision as to which approach should be selected in any given patient is dependent up patient preference and the availability and experience of the operator and institution at which the patient is being treated.",
keywords = "athletes, blood pressure, cardiomyopathy, hypertrophic, dyspnea, hypertrophy",
author = "Nishimura, {Rick A.} and Hubert Seggewiss and Schaff, {Hartzell V}",
year = "2017",
month = "9",
day = "15",
doi = "10.1161/CIRCRESAHA.116.309348",
language = "English (US)",
volume = "121",
pages = "771--783",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Hypertrophic Obstructive Cardiomyopathy

T2 - Surgical Myectomy and Septal Ablation

AU - Nishimura, Rick A.

AU - Seggewiss, Hubert

AU - Schaff, Hartzell V

PY - 2017/9/15

Y1 - 2017/9/15

N2 - Hypertrophic cardiomyopathy is a genetic disorder characterized by marked hypertrophy of the myocardium. It is frequently accompanied by dynamic left ventricular outflow tract obstruction and symptoms of dyspnea, angina, and syncope. The initial therapy for symptomatic patients with obstruction is medical therapy with β-blockers and calcium antagonists. However, there remain a subset of patients who have continued severe symptoms, which are unresponsive to medical therapy. These patients can be treated with septal reduction therapy, either surgical septal myectomy or alcohol septal ablation. When performed by experienced operators working in high-volume centers, septal myectomy is highly effective with a >90% relief of obstruction and improvement in symptoms. The perioperative mortality rate for isolated septal myectomy in most centers is <1%. Alcohol septal ablation is a less invasive treatment. In many patients, the hemodynamic and clinical results are comparable to that of septal myectomy. However, the results of alcohol septal ablation are dependent on the septal perforator artery supplying the area of the contact between the hypertrophied septum and the anterior leaflet of the mitral valve. There are some patients, particularly younger patients with severe hypertrophy, who do not uniformly experience complete relief of obstruction and symptoms. Both techniques of septal reduction therapy are highly operator dependent. The final decision as to which approach should be selected in any given patient is dependent up patient preference and the availability and experience of the operator and institution at which the patient is being treated.

AB - Hypertrophic cardiomyopathy is a genetic disorder characterized by marked hypertrophy of the myocardium. It is frequently accompanied by dynamic left ventricular outflow tract obstruction and symptoms of dyspnea, angina, and syncope. The initial therapy for symptomatic patients with obstruction is medical therapy with β-blockers and calcium antagonists. However, there remain a subset of patients who have continued severe symptoms, which are unresponsive to medical therapy. These patients can be treated with septal reduction therapy, either surgical septal myectomy or alcohol septal ablation. When performed by experienced operators working in high-volume centers, septal myectomy is highly effective with a >90% relief of obstruction and improvement in symptoms. The perioperative mortality rate for isolated septal myectomy in most centers is <1%. Alcohol septal ablation is a less invasive treatment. In many patients, the hemodynamic and clinical results are comparable to that of septal myectomy. However, the results of alcohol septal ablation are dependent on the septal perforator artery supplying the area of the contact between the hypertrophied septum and the anterior leaflet of the mitral valve. There are some patients, particularly younger patients with severe hypertrophy, who do not uniformly experience complete relief of obstruction and symptoms. Both techniques of septal reduction therapy are highly operator dependent. The final decision as to which approach should be selected in any given patient is dependent up patient preference and the availability and experience of the operator and institution at which the patient is being treated.

KW - athletes

KW - blood pressure

KW - cardiomyopathy, hypertrophic

KW - dyspnea

KW - hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=85030613629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030613629&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.116.309348

DO - 10.1161/CIRCRESAHA.116.309348

M3 - Review article

C2 - 28912182

AN - SCOPUS:85030613629

VL - 121

SP - 771

EP - 783

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 7

ER -